CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
CCTG is pleased to announce that the 2026 Annual Spring Meeting of Participants will be held April 24-26, 2026, at the Chelsea Hotel in Toronto.
On Monday May 27th CCTG launched a new look for our website.
The objectives for the new look:
Strategic design principles were applied to enable our multiple target audiences to find the relevant content for them. The CCTG site has historically been a tool for the CCTG trial management audience and is now also enabled to communicate to patients and families, our partners and donors.
Website target audiences:
MAC26 (S1706) trial has been centrally activated, this is a Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
CCTG Spring meeting travel expenses are reimbursed only by submitting a properly completed travel expense claim form. This form, accompanied by original documents, should be submitted to CCTG Group Administrator’s Office no later than 30 June 2019.
Dr. Khalil Sultanem is a Radiation Oncologist working at the Jewish General Hospital at McGill University. He is involved in the Head and Neck disease site committee at CCTG and is the Co-Chair of the HN9 study. Dr. Sultanem believes the HN9 study is a unique and innovative study because it provides a possibility to replace chemotherapy, which is toxic, with immunotherapy.
The Canadian Cancer Trials Group (CCTG) has been awarded more than 19 million USD over six years (approximately $25 million CAD) from the U.S. National Institutes of Health (NIH) and National Cancer Institute (NCI). This award will allow the group to continue their work leading major cancer clinical trials in Canada through the US National Clinical Trials Network (NCTN) and to develop new large scale trials under CCTG leadership.
A primary publication for the CCTG IND219 - A Randomized Phase II Trial of Selumetinib in Patients Receiving Standard Pemetrexed and Platinum-Based Chemotherapy for the Treatment of Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer
CCTG HNC2 (NRG HN004) - Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin Has now been centrally activated in Canada, the trial is being led by NRG Oncology in the US, and CCTG is sponsor in Canada.
Every year at the CCTG Spring Meeting we recognize individuals who have contributed significantly to the mission and activities of the Canadian Cancer Trials Group. Presentation of the awards will happen at the Recognition Awards Ceremony on Friday May 3 from 5:30 to 6:00 at the Chelsea Hotel in Toronto. We are honored to acknowledge the 2019 CCTG Recognition Awards winners.
